Peripartum cardiomyopathy-diagnosis, management, and long term implications

Trends in Cardiovascular Medicine

Volumn 29, Issue 3, 2019, Pages 164-173

  Stergiopoulos, Kathleen ^a   Lima, Fabio V ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Management; Outcomes; Peripartum cardiomyopathy

Indexed keywords

CONTRACEPTIVE AGENT; CARDIOVASCULAR AGENT;

BREAST FEEDING; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HUMAN; LABOR MANAGEMENT; LONG TERM CARE; OUTCOME ASSESSMENT; PERIPARTUM CARDIOMYOPATHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; CONGESTIVE CARDIOMYOPATHY; CONVALESCENCE; DRUG EFFECT; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PUERPERAL DISORDER; TIME FACTOR; TREATMENT OUTCOME;

CARDIOMYOPATHY, DILATED; CARDIOVASCULAR AGENTS; FEMALE; HUMANS; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PUERPERAL DISORDERS; RECOVERY OF FUNCTION; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 85051406909     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2018.07.012     Document Type: Review

References (67)

1. Richie, C, Clinical contributions to the pathology, diagnosis, and treatment of certain chronic disease of the heart. Edinburg Med Surg J, 2(333), 1849.
2. Demakis, JG, Rahimtoola, SH, Peripartum cardiomyopathy. Circulation 44:5 (1971), 964–968.
3. Pearson, GD, Veille, JC, Rahimtoola, S, Hsia, J, Oakley, CM, Hosenpud, JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. J Am Med Assoc 283:9 (2000), 1183–1188.
4. Sliwa, K, Hilfiker-Kleiner, D, Petrie, MC, Mebazaa, A, Pieske, B, Buchmann, E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12:8 (2010), 767–778.
5. Elkayam, U, Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 58:7 (2011), 659–670.
6. Sotiropoulou, PK, Lima, FV, Yang, J, Xu, J, Stergiopoulos, K, National trends and in-hospital outcomes during delivery in pregnant women with heart disease in the US. Circulation, 134(A11980), 2016.
7. Lima, FV, Yang, J, Xu, J, Stergiopoulos, K., National Trends and In-hospital Outcomes during Delivery among Pregnant Women with Heart Disease in the US. Am J Cardiol 119:10 (2017), 1694–1700.
8. Kolte, D, Khera, S, Aronow, WS, Palaniswamy, C, Mujib, M, Ahn, C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc, 3(3), 2014, e001056.
9. Lima, FV, Parikh, PB, Zhu, J, Yang, J, Stergiopoulos, K, Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery. JACC Heart Fail 3:3 (2015), 257–266.
10. Sliwa, K, Mebazaa, A, Hilfiker-Kleiner, D, Petrie, MC, Maggioni, AP, Laroche, C, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail, 2017, 1131–1141.
11. Goland, S, Modi, K, Bitar, F, Janmohamed, M, Mirocha, JM, Czer, LS, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 15:8 (2009), 645–650.
12. Elkayam, U, Tummala, PP, Rao, K, Akhter, MW, Karaalp, IS, Wani, OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 344:21 (2001), 1567–1571.
13. Sliwa, K, Forster, O, Zhanje, F, Candy, G, Kachope, J, Essop, R, Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol 93:11 (2004), 1441–1443 A10.
14. McNamara, DM, Elkayam, U, Alharethi, R, Damp, J, Hsich, E, Ewald, G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66:8 (2015), 905–914.
15. Ntusi, NB, Badri, M, Gumedze, F, Sliwa, K, Mayosi, BM, Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PloS One, 10(8), 2015, e0133466.
16. Gunderson, EP, Croen, LA, Chiang, V, Yoshida, CK, Walton, D, Go, AS, Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 118:3 (2011), 583–591.
17. Bello, N, Rendon, IS, Arany, Z, The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 62:18 (2013), 1715–1723.
18. Sliwa, K, Fett, J, Elkayam, U, Peripartum cardiomyopathy. Lancet 368:9536 (2006), 687–693.
19. Arany, Z, Elkayam, U, Peripartum cardiomyopathy. Circulation 133:14 (2016), 1397–1409.
20. Ware, JS, Li, J, Mazaika, E, Yasso, CM, DeSouza, T, Cappola, TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374:3 (2016), 233–241.
21. Arany, Z, Foo, SY, Ma, Y, Ruas, JL, Bommi-Reddy, A, Girnun, G, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451:7181 (2008), 1008–1012.
22. Patten, IS, Rana, S, Shahul, S, Rowe, GC, Jang, C, Liu, L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:7398 (2012), 333–338.
23. Halkein, J, Tabruyn, SP, Ricke-Hoch, M, Haghikia, A, Nguyen, NQ, Scherr, M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123:5 (2013), 2143–2154.
24. Bajou, K, Herkenne, S, Thijssen, VL, D'Amico, S, Nguyen, NQ, Bouche, A, et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med 20:7 (2014), 741–747.
25. Haghikia, A, Kaya, Z, Schwab, J, Westenfeld, R, Ehlermann, P, Bachelier, K, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol, 110(6), 2015, 60.
26. Kfoury, A., Rasmusson, K., Brunisholz, K., Port, T., Horne, B., Peripartum Cardiomyopathy. Stergiopoulos, K., Brown, D., (eds.) Evidence-Based Cardiology Consult, 2014, Springer-Verlag, London, 471–480.
27. Tanous, D, Siu, SC, Mason, J, Greutmann, M, Wald, RM, Parker, JD, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 56:15 (2010), 1247–1253.
28. Hu, CL, Li, YB, Zou, YG, Zhang, JM, Chen, JB, Liu, J, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 93:4 (2007), 488–490.
29. Stergiopoulos, K, Shiang, E, Bench, T, Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 58:4 (2011), 337–350.
30. Ahmed, R, Dunford, J, Mehran, R, Robson, S, Kunadian, V, Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 63:18 (2014), 1815–1822.
31. Dennis, AT, Castro, JM, Echocardiographic differences between preeclampsia and peripartum cardiomyopathy. Int J Obstet Anesth 23:3 (2014), 260–266.
32. Hilfiker-Kleiner, D, Sliwa, K, Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 11:6 (2014), 364–370.
33. Haghikia, A, Podewski, E, Libhaber, E, Labidi, S, Fischer, D, Roentgen, P, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol, 108(4), 2013, 366.
34. Hilfiker-Kleiner, D, Haghikia, A, Nonhoff, J, Bauersachs, J, Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 36:18 (2015), 1090–1097.
35. Mouquet, F, Lions, C, de Groote, P, Bouabdallaoui, N, Willoteaux, S, Dagorn, J, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 18:12 (2008), 2765–2769.
36. Hunt, SA, Abraham, WT, Chin, MH, Feldman, AM, Francis, GS, Ganiats, TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:14 (2009), e391–e479.
37. Ponikowski, P, Voors, AA, Anker, SD, Bueno, H, Cleland, JG, Coats, AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:27 (2016), 2129–2200.
38. Schubiger, G, Flury, G, Nussberger, J, Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 108:2 (1988), 215–216.
39. Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, Dudley, JA, Dyer, S, Gideon, PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:23 (2006), 2443–2451.
40. Widerhorn, J, Rubin, JN, Frishman, WH, Elkayam, U, Cardiovascular drugs in pregnancy. Cardiology Clin 5:4 (1987), 651–674.
41. Howlett, JG, McKelvie, RS, Costigan, J, Ducharme, A, Estrella-Holder, E, Ezekowitz, JA, et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 26:4 (2010), 185–202.
42. Regitz-Zagrosek, V, Sex and gender differences in symptoms of myocardial ischaemia. Eur Heart J 32:24 (2011), 3064–3066.
43. Hilfiker-Kleiner, D, Struman, I, Hoch, M, Podewski, E, Sliwa, K, 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep 9:3 (2012), 174–182.
44. WHO. Medical eligibility criteria for contraceptive use. 5 ed., 2015, World Health Organization, Geneva.
45. Kovacs, AH, Harrison, JL, Colman, JM, Sermer, M, Siu, SC, Silversides, CK, Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol 52:7 (2008), 577–578.
46. Leonard, H, O'Sullivan, JJ, Hunter, S, Family planning requirements in the adult congenital heart disease clinic. Heart 76:1 (1996), 60–62 British Cardiac Society.
47. Duran, N, Gunes, H, Duran, I, Biteker, M, Ozkan, M, Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet: Off Org Int Fed Gynaecol Obstet 101:2 (2008), 137–140.
48. Sliwa, K, Forster, O, Tibazarwa, K, Libhaber, E, Becker, A, Yip, A, et al. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol 147:2 (2011), 202–208.
49. Fett, JD, Christie, LG, Carraway, RD, Murphy, JG, Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 80:12 (2005), 1602–1606.
50. Goland, S, Bitar, F, Modi, K, Safirstein, J, Ro, A, Mirocha, J, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail 17:5 (2011), 426–430.
51. Modi, KA, Illum, S, Jariatul, K, Caldito, G, Reddy, PC, Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol, 201(2), 2009 171 e1–5.
52. Irizarry, OC, Levine, LD, Lewey, J, Boyer, T, Riis, V, Elovitz, MA, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and Non-African American women. JAMA Cardiol 2:11 (2017), 1256–1260.
53. Blauwet, LA, Delgado-Montero, A, Ryo, K, Marek, JJ, Alharethi, R, Mather, PJ, et al. Right ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. Circ Heart Fail, 9(5), 2016.
54. Forster, O, Hilfiker-Kleiner, D, Ansari, AA, Sundstrom, JB, Libhaber, E, Tshani, W, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10:9 (2008), 861–868.
55. Mouquet, F, Mostefa Kara, M, Lamblin, N, Coulon, C, Langlois, S, Marquie, C, et al. Unexpected and rapid recovery of left ventricular function in patients with peripartum cardiomyopathy: impact of cardiac resynchronization therapy. Eur J Heart Fail 14:5 (2012), 526–529.
56. Elkayam, U, Goland, S, Pieper, PG, Silverside, CK, High-risk cardiac disease in pregnancy: part II. J Am Coll Cardiol, 2016, 502–516.
57. Elkayam, U, Jalnapurkar, S, Barakat, M, Peripartum cardiomyopathy. Cardiol Clin 30:3 (2012), 435–440.
58. Sliwa, K, Blauwet, L, Tibazarwa, K, Libhaber, E, Smedema, JP, Becker, A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:13 (2010), 1465–1473.
59. Hilfiker-Kleiner, D, Haghikia, A, Berliner, D, Vogel-Claussen, J, Schwab, J, Franke, A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38:35 (2017), 2671–2679.
60. Hopp, L, Haider, B, Iffy, L, Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement. Int J Cardiol 57:3 (1996), 227–232.
61. Iffy, L, O'Donnell, J, Correia, J, Hopp, L, Severe cardiac dysrhythmia in patients using bromocriptine postpartum. Am J Ther 5:2 (1998), 111–115.
62. Elkayam, U, Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 64:15 (2014), 1629–1636.
63. Hilfiker-Kleiner, D, Haghikia, A, Masuko, D, Nonhoff, J, Held, D, Libhaber, E, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 19:12 (2017), 1723–1728.
64. Fett, JD, Fristoe, KL, Welsh, SN, Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstetr: Off Org Int Fed Gynaecol Obstetr 109:1 (2010), 34–36.
65. Lampert, MB, Weinert, L, Hibbard, J, Korcarz, C, Lindheimer, M, Lang, RM, Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 176:1 Pt 1 (1997), 189–195.
66. Rasmusson, K, Brunisholz, K, Budge, D, Horne, BD, Alharethi, R, Folsom, J, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant 31:2 (2012), 180–186.
67. Koutrolou-Sotiropoulou, P, Lima, FV, Stergiopoulos, K, Quality of life in survivors of peripartum cardiomyopathy. Am J Cardiol 118:2 (2016), 258–263.